In the latest issue of AIMed magazine, the Japanese assistive robot roadmap article attributed the success of robotics in Japan to their traditional values of not wanting to seek help from others. Although US has a similar roadmap, the priority was more on opportunities and innovations rather than catering to the needs of the majority.

Although China prides herself to be “Factory Asia”, making fine replica of exclusive items and “made in China” label can be read almost anywhere in the World, her locals still show minimum confidence towards home-made goods. Coupled with the lack of know-how in patent drug manufacturing, this had not only led to illegal import of drugs from overseas but also an opportunity for AI medicine to step in.

Diversity is marked by human, culture and systems. When a team is employed to develop a machine, it is important for members to each represent a segment of these three components, or a part of the population who eventually uses the AI, will always regard it as a threat.

For example, Roomba the cleaning irobot launched some time ago failed to realize that some culture prefer to sleep on the floor rather than on bed. The fully automated function of this robotic cleaning help had thus led to an unhappy incident by sucking the hair of a  woman who happens to sleep on the floor.

Like many of the solutions out there, there is clearly no “one size fits all” for AI. In order to know its diversity, first of all, we have to know what is AI medicine like around the World.

You can sign up for this session here.

Session Focus: AI in medicine: Around the World

When: Thursday, December 13th 2018 (09.00-09.45)

A candid showcase of AI medicine developments around the World and how culture and diversified workforces has been the underlining force behind some of the creativity.

Attendees will gain the following knowledge:

Understand the importance of cultural differences and diversified workforces in AI medicine development.

Uncover some of the culturally influenced AI medicine innovations.

Learn the importance of diversified collaborations in AI medicine and related collaborations.

Benefit from an interactive sharing of diversified speakers and audiences from different backgrounds and coming from around the World.  


Anthony Chang, Chief Intelligence and Innovation Officer, CHOC and Founder of AIMed, USA

Leo Anthony Celi, Associate Professor of Medicine (part-time), Harvard Medical School; Principal Research Scientist, Massachusetts Institute of Technology, USA  

Zhangbo Zhang, Deputy director of the Medical Engineering Support Center and Director of Department of Biomedical Engineering, Chinese PLA General Hospital, China

Karen Cross, Co-Founder & CEO, Mimosa Diagnostic

Yu-Chuan (Jack) Li, Professor & College of Medical Science and Technology, Taipei Medical University, Taiwan

You can sign up for this session here.